Author(s):
Peddi Srinivasa Rao, Tirukkovalluri Siva Rao, B. B. V. Sailaja, Pallapati Suman, G. Jai Sri
Email(s):
sivaraotvalluri.16@gmail.com
DOI:
10.52711/0974-360X.2023.00393
Address:
Peddi Srinivasa Rao1,2, Tirukkovalluri Siva Rao1*, B. B. V. Sailaja1, Pallapati Suman1, G. Jai Sri1.
1Department of Chemistry, Andhra University, Visakhapatnam, 530003, Andhra Pradesh, India.
2Srini Pharmaceuticals Pvt. Limited, Sy. No.: 247, Choutuppal, 508252, Yadadri Bhuvanagiri District, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 5,
Year - 2023
ABSTRACT:
A new simple, rapid, accurate and stability indicating RP-HPLC method have been developed and validated for estimation of Pretomanid is an anti-bacterial agent in pharmaceutical dosage form. The RP-HPLC analysis was performed by using Xtimate C18 column (250mm × 4.6mm; 5µm) with Methanol: Acetonitrile: Ammonium phosphate buffer in the ratio of 55:40:05 (v/v/v) as mobile phase at a flow rate of 1.0mL/min and detected at 262nm wavelength. The calibration curve was linear over the concentration range from 10 to 40µg/mL and correlation coefficient was found to be 0.99. LOD and LOQ were estimated as 0.30µg/mL and 5.0µg/mL respectively. The % recovery was achieved from 98.67% to 99.96%. The method was applied for estimation in its pharmaceutical dosage form and assay result was 98.9% label claim. Proposed method showed excellent linearity, accuracy, precision, specificity, robustness, LOD, LOQ, and system suitability results within the acceptance criteria as per ICH guidelines. The Pretomanid drug was subjected to stress condition of Hydrolysis, Oxidation, Photolysis and Thermal degradation, Forced degradation study was carried out and the degradation products were well resolved from the pure Pretomanid drug. The proposed method was successfully applied for the estimation of Pretomanid drugs in commercial dosage form.
Cite this article:
Peddi Srinivasa Rao, Tirukkovalluri Siva Rao, B. B. V. Sailaja, Pallapati Suman, G. Jai Sri. Stability Indicating RP-HPLC Method Development and Validation for the determination of Pretomanid an anti-bacterial drug. Research Journal of Pharmacy and Technology 2023; 16(5):2385-2. doi: 10.52711/0974-360X.2023.00393
Cite(Electronic):
Peddi Srinivasa Rao, Tirukkovalluri Siva Rao, B. B. V. Sailaja, Pallapati Suman, G. Jai Sri. Stability Indicating RP-HPLC Method Development and Validation for the determination of Pretomanid an anti-bacterial drug. Research Journal of Pharmacy and Technology 2023; 16(5):2385-2. doi: 10.52711/0974-360X.2023.00393 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-5-52
REFERENCES:
1. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. U.S. Food and Drug Administration (FDA) (Press release). 14 August 2019. Retrieved 28 August 2019.
2. Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, et al.Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2019;63(5):00021-19.doi: 10.1128/AAC.00021-19
3. Lyons MA.Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrob Agents Chemother. 2018; 62(7): 02359-17. doi: 10.1128/AAC.02359-17
4. Baptista R, Fazakerley DM, Beckmann M, Baillie L, Mur LAJ."Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)”. Scientific Reports. 2018; 8(1): 5084. doi: 10.1038/s41598-018-23110-1
5. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrobial Agents and Chemotherapy. 2005; 49 (6): 2294–2301.doi: 10.1128/AAC.49.6.2294-2301.2005
6. Kwon YS.Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis. Chonnam Medical Journal. 2017; 53(2):103-109.doi: 10.4068/cmj.2017.53.2.103
7. Bahuguna A, RawatDS.An overview of new antitubercular drugs, drug candidates, and their targets. Medicinal Research Reviews. 2019 ;40(5): 1-30.doi: 10.1002/med.21602.
8. L. Wang, Y. Xu, L. Liang, C. Diao, X. Liu,J. Zhang, Shengyong Zhang. Simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study.Journal of Pharmaceutical and Biomedical Analysis. 2014; (97):1-8.doi: 10.1016/j.jpba.2014.03.046.
9. L. Wang, Y. Ma, H. Duan, J. Yao, L. Liang, R. Zhang. Pharmacokinetics and tissue distribution study of PA-824 in rats.Journal of Chromatography B. 2015; (1006):194-200.doi: 10.1016/j.jchromb.2015.10.039.
10. D. Bratkowska, A. Shobo, S. Singh, L.A. Bester, H.G. Kruger, G.E. Maguire, ThavendranGovender. Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: Application to a pharmacokinetic study. Journal of Chromatography B. 2015; (988):187-194.doi: 10.1016/j.jchromb.2015.02.041
11. K.E. Dooley, A.F. Luetkemeyer, J.-G. Park, R. Allen, Y. Cramer, S. Murray, et al. Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. Antimicrobial Agents and Chemotherapy. 2014; 9(58): 5245-5252.doi: 10.1128/AAC.03332-14
12. Jakub Jireš , Stanislav Kalášek, Petr Gibala , Jakub Rudovský , Michal Douša, Tomáš Kubelka, Jan Hrubý , Pavel Řezanka .Insight into the formation of N-nitrosodimethylamine in metformin products. Journal of Pharmaceutical and Biomedical Analysis. 2021; 195: 1113885.doi: 10.1016/j.jpba.2020.113877.
13. M.A. Momin, S.J. Thien, W. Krittaphol, S.C. Das. Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of Pharmaceutical and Biomedical Analysis. 2017;(135):133.http://dx.doi.org/10.1016/j.jpba.2016.11.046
14. Bhoomi P. Shah, Suresh Jain, Krishna K. Prajapati ,Nasimabanu Y. Mansuri.stability indicating hplc method development: a review. International Journal of Pharmaceutical Sciences and Research. 2012; 3(9): 2978-2988. http://dx.doi.org/10.13040/IJPSR.0975-8232.3(9).2978-88
15. Kevita D’Souza, Alisha Syeda, Parnika Khatal, Muddukrishna Badamane Sathyanarayana, Vasantharaju SG. Stability Indicating Assay Method Development and Validation for Simultaneous Estimation of Ofloxacin and Ornidazole by RP-HPLC in Bulk: An Application to Tablet Formulation and Dissolution Studies. Indian Journal of Pharmaceutical Education and Research. 2021; 55(2):607-613.https://doi.org/10.5530/ijper.55.2.100
16. VishwasPardhi, Geetanjali Pant, S.J.S. Flora.RP-HPLC method development and validation for bedaquilinefumarate to evaluate its forced degradation behaviour and stability in official dissolution media.Future Journal of Pharmaceutical Sciences. (2020; 6(42):1-10. https://doi.org/10.1186/s43094-020-00061-x
17. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs - a review. Journal of Pharmaceutical Analysis. 2014;4(3):159–165. https://doi.org/10.1016/j.jpha.2013.09.003
18. ICH (2015). ICH harmanized tripartite guideline validation of analytical procedures: Federal Register, 2015; 62: 96.https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf
19. John W. Dolan.Stability-Indicating Assays. LC Troubleshooting 2005: 275.https://alfresco-static-files.s3.amazonaws.com/alfresco_images/pharma/2014/08/22/d660fddc-11ac-4979-a7a9-377e680bf6c2/article-17642.pdf
20. Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for conducting forced degradation studies. Pharm Tech. 2002:48-56.https://cdn.sanity.io/files/0vv8moc6/pharmtech/cef968de93fced22f668d7a89ec492e8dc542e12.pdf/article-9668.pdf
21. Swartz M. and Krull I. Developing and Validating Stability- Indicating Methods. LCGC North America. 2005; 23(6):586- 593.https://www.chromatographyonline.com/view/developing-and-validating-stability-indicating-methods-michael-swartz-and-ira-krull
22. Carr GP, Wahlich JC: A practical approach to method validation in pharmaceutical analysis. J Pharm Biomed Anal.1990;86:613-618.doi: 10.1016/0731-7085(90)80090-c
23. Xiao KP, Xiong Y, Liu FZ, Rustum AM. Efficient method development strategy for challenging separations of pharmaceutical molecules using advanced chromatographic technologies. J Chromatogr A, 2007; 1163:145–156. doi: 10.1016/j.chroma.2007.06.027
24. Ingole L. R. Development of Stability Indicating RP-HPLC Method for Estimation of ClemastineFumarate and its Pharmaceutical Dosage Form. Res. J. Pharma. Dosage Forms and Tech.2019; 10(2): 01-02. doi: 10.5958/0975-4377.2019.00014.4
25. B. Thangabalan, Ch. Sandhya, N. Sunitha, S. ManoharBabu. Stability Indicating RP-HPLC Method for the Estimation of Memantine Hydrochloride in Pure and Pharmaceutical Dosage Form. Research J. Pharma. Dosage Forms and Tech. 2013; 5(6): 334-340.doi: https://rjpdft.com/AbstractView.aspx?PID=2013-5-6-6
26. Sushil D. Patil, Tejashri Dugaje, Sanjay J. Kshirsagar. Development and Validation of HPLC Method for Estimation of Pharmaceutical Drug and its Stability Studies in Simulated Biological Fluid: Comparative Study. Asian J. Pharm. Tech. 2019; 9(3):179-184. doi: 10.5958/2231-5713.2019.00030.8
27. Awdhut D. Pimpale, Rajendra B. Kakde. Stability-Indicating Method Development and Validation for Estimation of ClopidogrelBisulfate in Pharmaceutical Dosage Form by Reverse-Phase High-Performance Liquid Chromatography. Asian J. Pharm. Res. 2020; 10(4):253-259. doi: 10.5958/2231-5691.2020.00044.1
28. Praful Sahare, Amit Nayak, Alok Pal Jain, Harikishor Barange. Development of Validated Analytical Methods and Stability Indicating studies for Pharmaceutical Formulation. Asian J. Pharm. Ana. 2021; 11(1):29-37. doi: 10.5958/2231-5675.2021.00006.5
29. Mohan Goud V, Tharun Goud G. Stability indicating high performance liquid chromatography method development and validation for simultaneous estimation of Glecaprevir and Pibrentasvir in bulk and pharmaceutical dosage form. Asian J. Pharm. Ana. 2020; 10(3): 141-146. doi: 10.5958/2231-5675.2020.00025.3
30. G. Indira Priyadarshini, V. Mounika, G. Anjani, B. Sowmya. Stability Indicating RP-HPLC Method Development and Validation for the Simultaneous Estimation of Tezacaftor and Ivacaftor in Bulk and Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2020; 10(1):19-26. doi: 10.5958/2231-5675.2020.00005.8
31. Sunita N Surse, Sushil D Patil, Kunal R Deshmukh, Sanjay J Kshirsagar. Development and Validation of Analytical Method by RP-HPLC and Forced Degradation Studies of Tioconazole Drug. Asian J. Pharm. Ana. 2019; 9(4):229-231.doi: 10.5958/2231-5675.2019.00039.5
32. PrasenjitMondal, Venu Kola. A New Stability Indicating Validated RP-HPLC Method for Simultaneous Estimation of Escitalopram and Clonazepam in Bulk and Tablet Dosage Form. Asian J. Pharm. Ana. 2019; 9(4):193-198.doi: 10.5958/2231-5675.2019.00032.2
33. M. T. Mohite, V. V. Dudhabale,K. V. Chandgude. Validation of Stability Indicating RP-HPLC, Method of Analysis for assay of Ivabradine HCl in SR Tablet. Asian J. Pharm. Ana. 2019; 9(3):133-137.doi: 10.5958/2231-5675.2019.00025.5
34. S. Muneer, Hindustan Abdul Ahad, Chandra SekharKothapalliBonnoth. A Novel Stability Indicating RP-HPLC Assay Method Development and Validation for the Quantification of Cyamemazine Tartrate in bulk and its Pharmaceutical Dosage Form. Asian J. Pharm. Ana. 2018; 8(3): 169-173. doi: 10.5958/2231-5675.2018.00031.5
35. B. Bhavya, P. Nagaraju, V. Mounika, G. Indira Priyadarshini. Stability Indicating RP-HPLC Method Development and Validation forSimultaneous Estimation of Albendazole and Ivermectin in Pharmaceutical Dosage form. Asian J. Pharm. Ana. 2017; 7(1): 6-14.doi: 10.5958/2231-5675.2017.00002.3